77 related articles for article (PubMed ID: 8614363)
1. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
Fountzilas G; Gossios K; Zisiadis A; Svarna E; Skarlos D; Pavlidis N
Med Pediatr Oncol; 1996 May; 26(5):305-17. PubMed ID: 8614363
[TBL] [Abstract][Full Text] [Related]
2. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.
Van Halteren HK; Roumen RM; Coebergh JW; Croiset van Uchelen FA; Keuning JJ; Vreugdenhil G
Anticancer Res; 1999; 19(4C):3447-9. PubMed ID: 10629633
[TBL] [Abstract][Full Text] [Related]
3. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yuste AL; Aparicio J; Segura A; López-Tendero P; Gironés R; Pérez-Fidalgo JA; Díaz R; Calderero V
Clin Colorectal Cancer; 2003 Feb; 2(4):231-4. PubMed ID: 12620142
[TBL] [Abstract][Full Text] [Related]
4. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Ishizuka M; Nagata H; Takagi K; Kubota K
Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
7. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
Assersohn L; Norman A; Cunningham D; Benepal T; Ross PJ; Oates J
Br J Cancer; 1999 Apr; 79(11-12):1800-5. PubMed ID: 10206296
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
10. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
[TBL] [Abstract][Full Text] [Related]
11. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
12. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
[TBL] [Abstract][Full Text] [Related]
15. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many?
Yan DB; Clingan P; Morris DL
Cancer; 2003 Jul; 98(2):320-30. PubMed ID: 12872352
[TBL] [Abstract][Full Text] [Related]
16. Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
Wang WS; Chen PM; Chiou TJ; Liu JH; Fan FS; Lin TC; Jiang JK; Yang SH; Yen CC; Wang HS; Lin JK
Hepatogastroenterology; 2000; 47(36):1590-4. PubMed ID: 11149009
[TBL] [Abstract][Full Text] [Related]
17. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
[TBL] [Abstract][Full Text] [Related]
18. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
20. Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Popov IP; Milicevic M; Kecmanovic D; Tomasevic Z; Radosevic-Jelic Lj; Borojevic N; Micev MT; Kezic I
J Exp Clin Cancer Res; 2006 Sep; 25(3):313-9. PubMed ID: 17167970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
